Bioelectrical Impedance Analysis and Mid-Upper Arm Muscle Circumference Can Be Used to Detect Low Muscle Mass in Clinical Practice

Dorienke Gort-van Dijk 1,2,*, Linda B.M. Weerink 3, Milos Milovanovic 3, Jan-Willem Haveman 4, Patrick H.J. Hemmer 4, Gerard Dijkstra 5, Robert Lindeboom 6,4 and Marjo J.E. Campmans-Kuijpers 5,4

1 Faculty of Medicine, University of Amsterdam/Amsterdam UMC, Master Evidence Based Practice in Health Care, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
2 Department of Nutrition and Dietetics, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 EZ Groningen, The Netherlands
3 Department of Radiology and Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 EZ Groningen, The Netherlands; lb.m.weerink@umcg.nl (L.B.M.W.); m.milovanovic@umcg.nl (M.M.)
4 Department of Surgery, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 EZ Groningen, The Netherlands; j.w.haveman@umcg.nl (J.-W.H.); p.h.j.hemmer@umcg.nl (P.H.J.H.)
5 Department of Gastroenterology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9713 EZ Groningen, The Netherlands; gerard.dijkstra@umcg.nl (G.D.); m.j.e.campmans-kuijpers@umcg.nl (M.J.E.-C.K.)
6 Department of Epidemiology and Data Science, Amsterdam UMC, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; r.lindeboom@amsterdamumc.nl

* These authors contributed to this work equally.
† These authors contributed to this work equally.

Abstract: Identification of low muscle mass becomes increasingly relevant due to its prognostic value in cancer patients. In clinical practice, mid-upper arm muscle circumference (MAMC) and bioelectrical impedance analysis (BIA) are often used to assess muscle mass. For muscle-mass assessment, computed tomography (CT) is considered as reference standard. We investigated concordance between CT, BIA, and MAMC, diagnostic accuracy of MAMC, and BIA to detect low muscle mass and their correlation with the clinical outcome malnutrition provided with the Patient-Generated Subjective Global Assessment Short Form (PG-SGA SF). This cross-sectional study included adult patients with advanced esophageal and gastrointestinal cancer. BIA, MAMC, and PG-SGA SF were performed. Routine CT-scans were used to quantify psoas muscle index (PMI) and skeletal muscle area. Good concordance was found between CTPMI and both BIAPFM (fat free mass index) (ICC 0.73), and BIAASMI (appendicular skeletal muscle index) (ICC 0.69) but not with MAMC (ICC 0.37). BIAPFM (94%), BIAASMI (86%), and MAMC (86%) showed high specificity but low sensitivity. PG-SGA SF modestly correlated with all muscle-mass measures (ranging from −0.17 to −0.43). Of all patients with low muscle mass, 62% were also classified with a PG-SGA SF score of ≥4 points. Although CT remains the first choice, since both BIA and MAMC are easy to perform by dieticians, they have the potential to be used to detect low muscle mass in clinical practice.

Keywords: body composition; anthropometry; muscle mass; sarcopenia; computed tomography; bioelectrical impedance analysis; mid-upper arm muscle circumference; patient generated-subjective global assessment short form; advanced cancer

1. Introduction

Among patients with advanced cancer, malnutrition is common [1,2] and accompanied by weight loss [3] and loss of fat free mass (FFM) [4]. Poor nutritional status, particularly a low FFM, at the start of treatment is associated with a rising incidence of chemotherapy-related toxicity, a prolonged length of hospital stay after surgery, an increased risk of
postoperative complications, and mortality [5–9]. Therefore, identifying, prevention, and treatment of malnutrition might offer an opportunity to enhance quality of patient care, improve clinical outcomes, and reduce healthcare costs [10,11].

There is growing evidence that early and evidence-based dietary counselling leads to improved dietary intake (energy and protein), body weight, nutritional status, enhanced oncologic and quality of life outcomes, and reduced complications [12–16]. In the treatment of advanced cancer, assessment of muscle status serves as an important indicator for clinicians to decide whether or not to proceed with an intended cancer treatment [17,18]. Identification of low muscle mass becomes increasingly relevant due to its prognostic value in cancer patients [19]. However, low muscle mass is not routinely recognized in current practice, since the assessment of nutritional status is mainly based on overall weight loss or decreased body mass index (BMI) alone, which does not differentiate fat mass from muscle mass [20,21].

For the assessment of clinical outcomes, the Patient Generated-Subjective Global Assessment (PG-SGA) is an established tool to screen for malnutrition in oncology settings [22] and is adapted for this population by Ottery [23] using the SGA tool developed by Detsky [24]. The PG-SGA consists of two parts: part one, known as the PG-SGA Short Form (PG-SGA SF), contains a self-assessment on the patient’s weight, food intake, symptoms, and functional ability. Part two assesses the metabolic demands of the disease and its impact on nutritional requirements and includes a physical examination of muscle mass and metabolic abnormalities by a trained clinician. It is a rapid, cost-effective, and feasible tool, which can easily be implemented in clinical settings, but its relation with measures of muscle mass is less well known [25].

For an accurate examination of nutritional status and to support clinical decision making, measurements of body composition, in particular muscle mass, are essential. There are various methods of body composition assessment. Presently, computed tomography (CT) and magnetic resonance imaging (MRI) are considered the reference standards to assess body composition in research [26]. CT provides precise segmentations of individual muscle and adipose tissue components. The total skeletal muscle mass based on CT estimation of the skeletal muscle area at the third lumbar vertebra (L3) is strongly correlated with total body skeletal muscle mass [27,28]. However, routine use of CT images for detection of low muscle mass in clinical dietary practice is limited. Additionally, dieticians are generally not trained to assess these scans [29,30].

Less demanding anthropometric methods, which can be performed by dieticians, include the mid upper-arm muscle circumference (MAMC) and bioelectrical impedance analysis (BIA). BIA measures the opposition (impedance) to the flow of an electrical current passed through the body, whereby impedance and its components, resistance, and reactance are quantitatively related to body water and, hence, fat-free mass [31]. Both MAMC and BIA are quick, easy, non-invasive, and non-expensive [32,33]. The importance of accurate assessment of muscle mass and identification of at-risk patients is increasingly recognized in clinical practice [34].

Currently, two studies on muscle loss in patients with advanced cancer are being conducted at the University Medical Centre Groningen (UMCG). In both studies, measurements of body composition parameters, including muscle mass, are measured with CT, BIA, and MAMC. Additionally, nutritional status is assessed with the PG-SGA.

The aim of this study was to examine concordance between CT-, BIA-, and MAMC-measures of muscle mass. The second aim was to investigate diagnostic accuracy of MAMC and BIA to detect low muscle mass. Furthermore, we examined their relation to a clinical outcome as assessed with the PG-SGA SF. Finally, we examined how conventional PG-SGA SF cut-offs for malnutrition relate to the diagnosis of low muscle mass as measured with CT.
2. Materials and Methods

2.1. Study Sample

Data was obtained from two studies on muscle loss in adult patients with advanced cancer. The first study concerns the study “Sarcopenia Preventing in Oesophagectomy Trial (SPOT)” (Trial NL6179 (NTR6326)). This intervention study aims to investigate whether a goal directed nutritional support can reduce sarcopenia (muscle loss) and the incidence of anastomotic leakage and pneumonia and prolong survival in oncological patients undergoing chemoradiotherapy and esophagectomy. The second study concerns the study “Sarcopenia and Malabsorption after HIPEC (SMal-HIPEC)” (Trial NL5961 (NTR6327)). The SMal-HIPEC study is a prospective observational study on high-risk surgical oncological patients with peritonitis carcinomatosa undergoing cytoreductive surgery and a HIPEC procedure. The aim is to investigate predictive factors for sarcopenia and malabsorption and identify prognostic factors for the incidence of anastomotic leakage, pneumonia, length of stay, readmission rate, and survival. Both studies are ongoing since 2017 at the UMCG. Therefore, this cross-sectional study included two samples. Both studies adhered to the Helsinki declaration, and METC approval was obtained [35]. Written informed consent was obtained for all participants. For the current study, patients were excluded if they wore a pacemaker or electronic implantable devices, since that precludes bio-electrical impedance.

2.2. Procedures

2.2.1. Assessment of Muscle Mass by Computed Tomography Scan

CT scans completed for initial cancer staging and routine diagnostic purposes were used to quantify psoas muscle and skeletal muscle areas. Axial CT images obtained on the level of the third lumbar vertebra (L3) were used to calculate muscle surface. The most cranial slice, clearly displaying both transverse processes of the third lumbar vertebra, was used. All CT images were obtained 60–70 s after the administration of intravenous iodized contrast media. The thinnest available slice thickness, generally 1 mm, was used. Muscle mass was determined by manual outlining of the total cross-sectional area of both psoas muscles (total psoas area, TPA, mm$^2$) and the total cross-sectional skeletal muscle area (SMA, cm$^2$). The maximum surface area of both psoas muscles combined was used in the analysis. The measurements were performed by an experienced radiologist in training (LBMW) and a trained researcher (MM) with the use of imaging analysis software (Aquarius Intuition, Terarecon Inc., Foster City, CA, USA). These assessors were blinded to the outcome of the other measurements. The intra-observer correlation was 0.98 for SMA and 0.96 for TPA. The inter-observer correlation was 0.96 for SMA and 0.91 for TPA. TPA was normalized for patient height to calculate the psoas muscle index (PMI) in mm$^2$/m$^2$ and SMA was normalized for height to calculate the skeletal muscle index (SMI) in cm$^2$/m$^2$. Low muscle mass was defined using the sex-specific lowest quartile for the PMI as the cut-off point, as described in a study of Ozawa et al. [36]. For SMI, low muscle mass was defined using the cut-off point, according to Martin et al. [4]: SMI < 41 cm$^2$/m$^2$ for women; SMI < 43 cm$^2$/m$^2$ for men with BMI < 25 kg/m$^2$; and SMI 53 cm$^2$/m$^2$ for men with BMI ≥ 25 kg/m$^2$. To keep accuracy as high as possible, CT scans that performed closest to the data of the other muscle mass assessed on the baseline were used.

2.2.2. Assessment of Muscle Mass by Bio-Electrical Impedance Analysis

BIA was analyzed in patients with a portable, multi-frequency eight-point Seca medical Body Composition Analyzer mBCA525. Waist circumference was measured from the mid-level between the iliac crest and the lowest rib. Patients were instructed to lie supine on a (hospital) bed with no limbs touching the body during the actual measurement. Fat mass and fat free mass were calculated using the regression equation of the manufacturer [37]. The fat-free-mass index (FFMI) was considered the primary BIA measure. The FFMI was calculated by the following equation: (total body weight [kg]—fat mass [kg])/height [m$^2$]. Low muscle mass was defined using the cut-off point according to Schutz et al. [38]: the FFMI less than the 10th percentile of an age-matched and sex-matched Caucasian popu-
lation was considered for the diagnosis of low muscle mass. As an additional parameter, the appendicular skeletal muscle index (ASMI) calculated from the appendicular skeletal muscle mass (ASMM) was used. The ASMI was calculated using Sergi's formula [39] by the following equation: \( \text{ASMM [kg]} = -3.964 + (0.227 \times \text{RI}) + (0.095 \times \text{weight}) + (1.384 \times \text{sex}) + (0.064 \times Xc) \). Thereafter, the ASMI was normalized for height to calculate the ASMI in kg/m². Low muscle mass was defined using the cut-off point, according to Gould et al. [40]: the ASMI < 7.0 kg/m² for men and the ASMI < 5.5 kg/m² for women were considered for the diagnosis of low muscle mass.

2.2.3. Assessment of Muscle Mass by Mid Upper-Arm Muscle Circumference

Weight and height were recorded according to the standard methods from which BMI was calculated (weight [kg]/height [m²]). Mid upper-arm circumference was measured at the midpoint between the tip of the shoulder and the elbow on the non-dominant side of the body using a flexible tape, read to the nearest 0.1 cm. Triceps skin fold thickness measurements were performed with a Harpenden skinfold caliper (British indicators Ltd., St Albans, Herts, UK), read to the nearest 0.2 cm. Mid upper-arm muscle circumference (MAMC) was calculated: \( \text{MAMC [mm]} = \text{mid upper-arm circumference [mm]} - (3.14 \times \text{triceps skin fold thickness [mm]}) \). Low muscle mass was defined using the cut-off point according to Frisancho [41]: MAMC less than the 10th percentile of an age-matched and sex-matched Caucasian population was considered for the diagnosis of low muscle mass.

2.2.4. Assessment of Nutritional Status by PG-SGA SF

The PG-SGA is a validated questionnaire to assess nutritional status [22,23,42]. The score of the complete PG-SGA ranges between 0–52 points. The PG-SGA SF, which can be completed by the patients themselves in 5 min, contains the first four boxes, with scores ranging between 0–36 points [43]. Box 1: weight (history) and acute weight changes (scores 0–5); Box 2: food intake over the past month (scores 0–4); Box 3: nutrition impact symptoms experienced over the previous 2 weeks (scores 0–23); and Box 4: activity and functioning over the previous month (scores 0–4). The total score of these four boxes determine the level of nutritional risk according to prespecified nutritional triage recommendations: scores 0–1 (no intervention, regular reassessment), scores 2–3 (patient and family education by a dietician or nurse as indicated by symptoms), scores 4–8 (intervention by a dietician in conjunction with nurse or physician, as indicated by symptoms), and scores ≥9 (critical need for improved symptom management and/or nutritional intervention options) [23].

In accordance with the PG-SGA triage system, a PG-SGA SF total score of 0–3 points was categorized as low risk, 4–8 points as medium risk, and ≥9 points as high risk for malnutrition [44,45]. Cut-offs used for analysis were based on this triage system and set as follows: medium/high risk (≥4 points) and high risk (≥9 points).

2.2.5. Assessment of Dietary Intake

Dietary intake was assessed by 24 h recall. Calories and proteins were then calculated using nutritional calculation software (Evry).

2.3. Statistical Analysis

Descriptive data were reported as mean and standard deviation (SD) if normally distributed, otherwise in median and interquartile range (IQR, 25–75%). Normality of data was checked by visual assessment and using Shapiro–Wilk tests. In case of violation of the normality assumption, nonparametric statistics were used. After converting to z-scores, the Intraclass Correlation Coefficient (model1, one-way agreement) was calculated to determine the concordance between CT, BIA, and MAMC. ICCs less than 0.40 were considered as ‘poor’, between 0.40–0.59 as ‘fair’, between 0.60–0.74 as ‘good’, and between 0.75–1.00 as ‘excellent’ [46]. In addition, differences between measures of CT, BIA, and MAMC were visualized with Bland–Altman plots, and limits of agreement were calculated. Cross tabulation was used to determine sensitivity, specificity, and the diagnostic odds
ratio (DOR) for BIA and MAMC measures in identifying low muscle mass using $CT_{PMI}$ as the reference standard. DOR is the ratio of the odds of a positive test result on BIA or MAMC in patients with low muscle mass relative to the odds in patients without low muscle mass [47].

Spearman’s rank correlation coefficients were used to examine the relation between the PG-SGA SF and the muscle mass measurements. To evaluate how the conventional PG-SGA SF cut-offs for malnutrition and diagnoses of low muscle relate, we compared the median PG-SGA score and numbers of malnutrition cases among low and normal muscle mass subjects. All statistical analysis were performed by using R version 3.5.3.

3. Results

A total of 60 patients were initially included in the study. In four patients, BIA measurement could not be performed due to malfunction of the device. In addition, another seven patients were excluded because their CT-scans were unsuitable for muscle mass analysis. A total of 49 patients were included in the final analysis (Figure 1). Median age was 62.0 (IQR, 56.0–70.0) years and 53.1% were men. In 26.5% of the patients, BMI was $\geq 30$ kg/m$^2$. Most patients (91.8%) had no limitations in their activities or functioning and were ambulatory with fairly normal activities (PG-SGA SF box 4 score 0 or 1). One patient (2.1%) was not feeling up to most things and was in bed or a chair less than half the day (PG-SGA SF box 4 score 2), and three patients (6.1%) were only able to do little activity and spent most of the day in bed or a chair (PG-SGA SF box 4 score 3). BIA, MAMC, and PG-SGA SF were measured on the same day; in one patient only BIA was measured 1 week later. Median time between performing CT and other measurements was 14.0 (IQR, 12.0–34.0) days (Table 1).

![Figure 1. Flow chart of inclusion process.](image-url)
Table 1. Clinical characteristics of patients.

| Characteristics                          | All Patients (n = 49) | Men (n = 26) | Women (n = 23) |
|------------------------------------------|-----------------------|--------------|---------------|
| Age (years; median, IQR)                | 62.0 (56.0–70.0)      | 65.0 (57.0–68.5) | 62.0 (50.5–71.5) |
| Height (cm; mean (SD)                   | 174 ± 8.5             | 179 ± 6.2    | 167 ± 6.4    |
| Weight (kg; mean (SD)                   | 80.8 ± 17.1           | 88.7 ± 15.3  | 71.9 ± 14.6  |
| BMI (kg/m²; mean ± SD) ^               | 26.8 ± 5.0            | 27.7 ± 4.6    | 25.7 ± 5.4    |
| Underweight (n, %)                      | 1 (2.0)               | 0 (0.0)      | 1 (4.3)      |
| Normal weight (n, %)                    | 20 (40.8)             | 9 (34.6)     | 11 (47.8)    |
| Overweight (n, %)                       | 15 (30.6)             | 9 (34.6)     | 6 (26.1)     |
| Obesity or obese (n, %)                 | 13 (26.5)             | 8 (30.8)     | 5 (21.7)     |
| Weight loss past month ^                |                       |              |              |
| No weight loss (n, %)                   | 35 (71.4)             | 18 (69.2)    | 17 (74.0)    |
| 0–5% weight loss (n, %)                 | 9 (18.4)              | 6 (23.2)     | 3 (13.0)     |
| 5–10% weight loss (n, %)                | 2 (4.1)               | 1 (3.8)      | 1 (4.3)      |
| >10% weight loss (n, %)                 | 2 (4.1)               | 1 (3.8)      | 1 (4.3)      |
| Missing: 1                              |                       |              |              |
| Weight loss past 6 months ^             |                       |              |              |
| No weight loss (n, %)                   | 19 (38.8)             | 8 (30.8)     | 11 (47.8)    |
| 0–5% weight loss (n, %)                 | 14 (28.6)             | 9 (34.6)     | 5 (21.7)     |
| 5–10% weight loss (n, %)                | 6 (12.2)              | 3 (11.5)     | 3 (13.0)     |
| >10% weight loss (n, %)                 | 5 (10.2)              | 3 (11.5)     | 2 (8.7)      |
| Missing: 5                              |                       |              |              |
| Waist circumference (cm; mean ± SD) ^    | 99.8 ± 19.0           | 107 ± 20.1   | 91.5 ± 13.8  |
| Underweight (n, %)                      | 0 (0)                 | 0 (0)        | 0 (0)        |
| Healthy waist (n, %)                    | 13 (26.5)             | 8 (30.8)     | 5 (21.7)     |
| Overweight (n, %)                       | 9 (18.4)              | 3 (11.5)     | 6 (26.1)     |
| Obesity or obese (n, %)                 | 27 (55.1)             | 15 (57.7)    | 12 (52.2)    |
| Dietary intake (mean ± SD)              |                       |              |              |
| Calorie intake (kcal/d)                 | 1950 ± 461            | 2020 ± 399   | 1880 ± 516   |
| Calorie intake (kcal/kg)                | 25.6 ± 9.3            | 23.4 ± 6.6   | 27.8 ± 11.0  |
| Protein intake (gram/d)                 | 88.0 ± 20.1           | 92.2 ± 20.2  | 83.7 ± 19.6  |
| Protein intake (gram/kg)                | 1.2 ± 0.4             | 1.1 ± 0.3    | 1.2 ± 0.4    |
| Missing: 5                              |                       |              |              |
| PAL (median, IQR)                       | 1.8 (1.6–1.8)         | 1.8 (1.6–1.8) | 1.8 (1.6–1.8) |
| Diagnosis (n, %)                        |                       |              |              |
| Esophageal cancer                       | 24 (51)               | 18 (69.2)    | 6 (26)       |
| Peritonitis Carcinomatosa               | 25 (49)               | 8 (30.8)     | 17 (74)      |
| Time between CT and BIA, MAMC, PG-SGA SF (days; median, IQR) | 14.0 (12.0–34.0) | 13.0 (10.3–20.4) | 19.0 (12.0–43.0) |

BMI, body mass index; PAL, physical activity level (energy expenditure); CT, computed tomography; BIA, bioelectrical impedance analysis; MAMC, mid-upper arm muscle circumference; PG-SGA SF, patient generated-subjective global assessment short form; WHO, world health organization; NHG, Dutch general practitioner society. ^ WHO categories: underweight BMI < 18.5, normal 18.50–24.99, overweight ≥ 25, obesity or obese ≥ 30. According to the PG-SGA SF ^ NHG categories: underweight <79 cm (m) or <68 cm (w), healthy waist 79–94 cm (m) or 68–80 cm (w), overweight 94–102 cm (m) or 80–88 cm (w), obesity or obese ≥ 102 cm (m) or ≥88 cm (w).

Table 2 shows outcomes of the muscle mass measurements derived from CT, BIA, and MAMC and outcomes of the PG-SGA SF. For the total sample, mean CT_{SMI} was 45.5 ± 13.4 cm²/m². Mean CT_{SMI} was higher in women than men, respectively, 47.8 ± 14.3 cm²/m² vs. 43.3 ± 12.4 cm²/m² (p = 0.25). Median CT_{PMI} was 58.0 (IQR, 50.0–71.0) mm²/m² and was higher in men 69.5 (IQR, 56.5–83.0) mm²/m² than women 53.0 (IQR, 44.0–59.0) mm²/m² (p < 0.05). For the total sample, mean BIA_{FFMI} was 18.8 ± 2.8 kg/m², mean BIA_{ASMI} was 7.0 ± 1.2 kg/m², both higher in men than in women (both p < 0.05). Mean MAMC for the total sample was 25.2 ± 4.7 cm and 26.7 ± 4.9 cm for men and 23.4 ± 3.7 cm for women (p = 0.01). The median PG-SGA SF score was 3.0 (IQR, 0.0–7.0) for the total sample. Twenty patients (40.8%) had a score of 4 points or more and eight patients (16.3%) had a score of ≥9 points.
Table 2. Measurements of muscle mass and PG-SGA SF.

|                          | All Patients (n = 49) | Men (n = 26) | Women (n = 23) |
|--------------------------|-----------------------|--------------|----------------|
| **CT<sub>SMI</sub> (mean ± SD)** | 45.5 ± 13.4           | 43.3 ± 12.4  | 47.8 ± 14.3    |
| Low muscle mass (n, %)   | 23 (46.9)             | 15 (57.7)    | 8 (34.8)       |
|                         | Missing: 1            | Missing: 1   |                |
| **CT<sub>PMI</sub> (median, IQR)** | 58.0 (50.0–71.0)     | 69.5 (56.5–83.0) | 53.0 (44.0–59.0) |
| Low muscle mass (n, %)   | 13 (26.5)             | 7 (26.9)     | 6 (26.1)       |
| **BIA<sub>FFMI</sub> (mean ± SD)** | 18.8 ± 2.8            | 20.6 ± 2.1   | 16.7 ± 1.7     |
| Low muscle mass (n, %)   | 5 (10.2)              | 3 (11.5)     | 2 (8.7)        |
| **BIA<sub>ASMI</sub> (mean ± SD)** | 7.0 ± 1.2             | 7.7 ± 0.9    | 6.2 ± 0.9      |
| Low muscle mass (n, %)   | 10 (20.4)             | 5 (19.2)     | 5 (21.7)       |
|                         | Missing: 1            | Missing: 1   |                |
| **MAMC (mean ± SD)**    | 25.2 ± 4.7            | 26.7 ± 4.9   | 23.4 ± 3.7     |
| Low muscle mass (n, %)   | 9 (18.4)              | 5 (19.2)     | 4 (17.4)       |
| **PG-SGA SF score (median, IQR)** | 3.0 (0.0–7.0)        | 1.0 (0.0–6.8) | 3.0 (1.0–6.0)  |
| ≥4 points (n, %)         | 20 (40.8)             | 11 (42.3)    | 9 (39.1)       |
| ≥9 points (n, %)         | 8 (16.3)              | 4 (15.4)     | 4 (17.4)       |

CT, computed tomography; SMI, skeletal muscle index (cm²/m²); PMI, psoas muscle index (mm²/m²); BIA, bioelectrical impedance analysis; FFMI, fat free mass index (kg/m²); ASMI, appendicular skeletal muscle index (kg/m²); MAMC, mid-upper arm muscle circumference (cm); PG-SGA SF, patient generated-subjective global assessment short form (points).

3.1. Concordance of Muscle Mass Measurements between CT, BIA, and MAMC

Concordance was calculated based on z-scores. Table 3 shows the concordance between CT-, BIA-, and MAMC- measurements of muscle mass. Concordance between CT<sub>SMI</sub> and CT<sub>PMI</sub> was poor (ICC −0.07), as was concordance between CT<sub>SMI</sub> and measurements derived from BIA<sub>FFMI</sub> (ICC −0.06), BIA<sub>ASMI</sub> (ICC −0.06), and MAMC (ICC −0.01). Concordance with CT<sub>PMI</sub> with both BIA<sub>FFMI</sub> (ICC 0.73) and BIA<sub>ASMI</sub> (ICC 0.69) were good. Concordance between CT<sub>PMI</sub> and MAMC (ICC 0.37) was fair. MAMC showed good concordance with BIA<sub>FFMI</sub> and BIA<sub>ASMI</sub>, with ICC 0.64 and ICC 0.71, respectively. Differences between methods with good concordance were plotted against the mean of the two measurements and are shown in Figure 2. The Bland–Altman analysis showed limits of agreement ranging from −1.45 to 1.45 z-score for CT<sub>PMI</sub> (corresponding to deviations ranging from 7.4% and 92.6% of the total possible range of the measures) and BIA<sub>FFMI</sub>, for CT<sub>PMI</sub> and BIA<sub>ASMI</sub>, limits of agreement ranging from −1.56 to 1.56 z-score (corresponding to deviations ranging from 5.9% and 94.1% of the total possible range of the measures). For BIA<sub>FFMI</sub> and MAMC, limits of agreement ranged from −1.69 to 1.69 z-score (corresponding to deviations ranging from 4.6% and 95.5% of the total possible range of the measures). For BIA<sub>ASMI</sub> and MAMC, limits of agreement ranged from −1.50 to 1.50 z-score (corresponding to deviations ranging from 6.7% and 93.3% of the total possible range of the measures).
Table 3. Intraclass correlations for the concordance based on z-scores between muscle mass measures.

|                | CT\_SMI | CT\_PMI | BIA\_FFMI | BIA\_ASMI | MAMC |
|----------------|---------|---------|-----------|-----------|------|
| CT\_SMI        | -0.07   | -0.06   | -0.07     | -0.01     |      |
| (95% CI)       | -0.35–0.21 | -0.33–0.23 | -0.34–0.22 | -0.29–0.27 |      |
| CT\_PMI        | -       | 0.73\(^a\) | 0.69\(^a\) | 0.37\(^a\) |      |
| (95% CI)       | -       | 0.57–0.84 | 0.51–0.81 | 0.1–0.59 |      |
| BIA\_FFMI      | -       | -       | -         | -         | 0.64\(^a\) |
| (95% CI)       | -       | -       | -         | -         | 0.44–0.78 |
| BIA\_ASMI      | -       | -       | -         | -         | 0.71\(^a\) |
| (95% CI)       | -       | -       | -         | -         | 0.54–0.83 |
| MAMC           | -       | -       | -         | -         | -     |

CT, computed tomography; SMI, skeletal muscle index; PMI, psoas muscle index; BIA, bioelectrical impedance analysis; FFMI, fat free mass index; ASMI, appendicular skeletal muscle index; MAMC, mid-upper arm muscle circumference. Interpretation: less than 0.40 ‘poor’; between 0.40–0.59 ‘fair’; between 0.6–0.74 ‘good’; between 0.75–1.00 ‘excellent’ [46]. \(^a\) \(p < 0.05\).

Figure 2. Bland–Altman plots showing absolute differences based on z-scores between muscle mass methods against the mean of the two measurements in the total sample.

3.2. Diagnostic Accuracy of BIA and MAMC to Identify Low Muscle Mass

Of the 49 study participants, 23 patients (46.9%, 15 men, 8 women) were identified as having low muscle mass based on CT\_SMI. Based on CT\_PMI, 13 patients (26.5%, 7 men, 6 women) were identified as having low muscle mass. Five patients (10.2%), three men and two women, were classified as having low muscle mass by BIA\_FFMI. Ten patients
(20.4%), five men and five women, were classified as having low muscle mass by BIA\textsubscript{ASMI}. Furthermore, nine patients (18.4%), five men and four women, were classified with low muscle mass by MAMC. In Table 4, we present the accuracy of BIA and MAMC in identifying patients with low muscle mass. The outcomes illustrate to which extent false positive and false negative BIA and MAMC outcomes contribute to the mismatch with CT\textsubscript{PMI}. For identification of low muscle mass, both BIA\textsubscript{FFMI}, BIA\textsubscript{ASMI}, and MAMC had low sensitivity. Specificity was high: 94%, 86%, and 86%, respectively. DORs were 5.1 for BIA\textsubscript{FFMI}, 3.8 for BIA\textsubscript{ASMI}, and 2.8 for MAMC.

### Table 4. Accuracy of BIA and MAMC in identifying patients with low muscle mass with CT\textsubscript{PMI} as the reference method.

|                      | True Positive (n) | False Positive (n) | False Negative (n) | True Negative (n) | Sensitivity | Specificity | DOR  |
|----------------------|-------------------|--------------------|--------------------|-------------------|-------------|-------------|------|
| BIA\textsubscript{FFMI} | 3                 | 2                  | 10                 | 34                | 23          | 94          | 5.1  |
| BIA\textsubscript{ASMI} | 5                 | 5                  | 8                  | 30                | 38          | 86          | 3.8  |
| MAMC                 | 4                 | 5                  | 9                  | 31                | 30          | 86          | 2.8  |

BIA, bioelectrical impedance analysis; FFMI, fat free mass index; ASMI, appendicular skeletal muscle index; MAMC, mid-upper arm muscle circumference; Sens, sensitivity; Spec, specificity; DOR, Diagnostic Odds Ratio.

#### 3.3. Relation between Muscle Mass Measurements with Clinical Outcome (PG-SGA SF)

PG-SGA SF showed modest negative correlations with CT\textsubscript{SMI} (rho = −0.17, p = 0.246) and BIA\textsubscript{ASMI} (rho = −0.43, p = 0.002). Meanwhile, correlations between PG-SGA SF and CT\textsubscript{PMI}, BIA\textsubscript{FFMI}, and MAMC were 0.32, 0.38, and 0.26, respectively.

#### 3.4. Low Muscle Mass and PG-SGA SF Cut-Offs for Malnutrition

In Table 5, we present the numbers with medium and high risk of malnutrition (PG-SGA SF cut-offs) among patients with low and normal total muscle mass according to CT\textsubscript{PMI}. For patients with low muscle mass, the median PG-SGA SF score was 5 (IQR, 2.0–9.0) compared to 1.5 (IQR, 0.0–6.0) for patients with normal muscle mass. Of the 13 patients with low muscle mass, 62% were classified as medium/high risk for malnutrition compared to 33% for patients with normal muscle mass. Using the PG-SGA SF $\geq$9 points cut-off for malnutrition, these were 31% and 11%, respectively. Patients with low muscle mass were 3.2 times more likely to be at medium/high risk for malnutrition and 3.6 more likely to be at high risk for malnutrition.

### Table 5. Prevalence of malnutrition (PG-SGA SF cut-offs) among patients with low and normal muscle mass.

|                      | Low Muscle Mass $^*$ | Normal Muscle Mass $^*$ |
|----------------------|----------------------|-------------------------|
|                      | (n = 13)             | (n = 36)                |
| PG-SGA SF score (median, IQR) | 5 (2.0–9.0)          | 1.5 (0.0–6.0)           |
| PG-SGA SF $\geq$4 points (n, %) | 8 (62)               | 12 (33)                 |
| PG-SGA SF $\geq$9 points (n, %) | 4 (31)               | 4 (11)                  |

PG-SGA SF, patient-generated subjective global assessment short form. $^*$According to CT\textsubscript{PMI}. All differences p > 0.05.

#### 4. Discussion

This study shows a high correlation between the z-scores for measuring muscle mass in surgical oncological patients for CT and BIA. Additionally, BIA and MAMC showed good concordance. However, Bland and Altman plots of z-score deviations were typically in the range of ±1.5, indicating large differences between muscle mass measures on individual levels, suggesting that BIA, MAMC, and CT cannot be used interchangeably. Using conventional cut-offs for low muscle mass for BIA\textsubscript{FFMI}, BIA\textsubscript{ASMI}, and MAMC, specificity was high, whereas sensitivity was low. Of all patients with low muscle mass, 62% were also
classified with a PG-SGA SF score of \( \geq 4 \) points, underscoring the importance of screening for muscle mass in clinical practice.

These findings correspond with results from previous studies on muscle mass measurements. A recent study by Looijaard et al. [48] on critically ill patients also showed significant correlations—ranging between 0.64–0.834—for different BIA-derived muscle mass equations and CT-derived measurements. Giusto et al. [49] found a rather weak correlation (0.48 for men and 0.18 for women) between MAMC with CT scan analysis of muscle mass in patients with liver cirrhosis. This corresponds to the correlation we found between MAMC and CT\( PMI \).

Both CT\( SMI \) and CT\( PMI \) have demonstrated that they are applicable for the assessment of muscle mass in patients with advanced cancer [4,36]. Remarkably, in our study, only CT\( PMI \) was related to BIA and MAMC assessment of muscle mass. Another notable finding was that women had higher muscle mass than men when measured with CT\( SMI \) (\( p = 0.25 \)), but not with CT\( PMI \) (\( p < 0.05 \)). This might be due to overrepresentation of men in the esophageal sample who were in worse nutritional status than the, mainly female, patients in the peritonitis carcinomatoses sample. Patients with esophageal cancer often experience nutritional intake problems at diagnosis [50]. However, it contradicts results of the other muscle mass measurements, where men overall showed higher muscle mass than women. The low correlation between CT\( PMI \) and CT\( SMI \) also suggests that these CT methods cannot be used interchangeably in our sample of oncologic patients. In line with our finding, a recent review and meta-analysis concluded that low psoas mass prior to surgery better predicts the development of postoperative complications than total skeletal muscle mass [51]. Another review also highlighted inconsistencies in current literature as to defining muscle mass parameters measured by a CT scan and emphasized the need for standardized protocols and definitions [52].

Early identification of (risk of developing) low muscle mass may lead to more timely nutritional support which, in turn, may benefit the prognosis of patients under treatment for cancer [53]. Therefore, more accurate and routine measurement of muscle mass in clinical practice is crucial for aligning appropriate interventions to prevent any further muscle loss. BIA and MAMC both underestimated the presence of low muscle mass in our study. This implies that neither of these two methods can match the precision of CT scans. As has been shown in previous research, transverse CT images on the level of the third lumbar vertebra (L3) strongly correlates with total body skeletal muscle area in patients with cancer [27,54], whereas MAMC only represents the arms and can only be determined indirectly by measuring mid upper arm circumference and triceps skinfold thickness. Fluid imbalance, often occurring in cancer patients, can result in an erroneous measurement of BIA [55]. However, both BIA and MAMC showed high specificity at the conventional cut-offs used in screening, which makes these instruments suitable for detecting low muscle mass in patients, in both clinical and primary care settings where assessment of muscle mass with CT scan is not feasible. Therefore, both BIA and MAMC might be well suited for routinely assessment of muscle mass, especially because they are widely available, non-expensive, and relatively easy to perform.

Among patients with low muscle mass, 62% were also classified with a PG-SGA SF score of \( \geq 4 \) points, indicating medium/high risk for malnutrition. Since malnutrition is accompanied with loss of muscle mass, identification of patients at risk for malnutrition seems relevant in clinical practice to prevent further progression of low muscle mass [56]. Recently, a review of Deutz et al. also emphasized the relationship between low muscle mass and malnutrition and therefore the need for screening patients [57]. Nevertheless, our study demonstrated that the PG-SGA SF and muscle mass measurements with CT, BIA, and MAMC cannot be used interchangeably. However, CT image analysis effectively adds value to nutrition screening [58].

There are some limitations to consider regarding the body composition measurement techniques used in this study. Although BIA has extensively been validated as a body composition measurement tool, hydration status can affect resistance measured by BIA [59].
As fluid shifts are common in patients with cancer, BIA measurements may have overestimated fat-free mass and thus underestimated the presence of low muscle mass. In addition, MAMC measurements are subject to variability as observers need to be experienced in the measurement technique. Different observers carried out the MAMC measurements, which may have affected its reliability. Furthermore, only 49 subjects could be included. This may have limited our analysis and affected our results. We recommend the conduct of a study with a larger sample. The strength of this study was that all measurements, except CT, were performed on the same day, allowing a direct comparison between the clinical values of the available muscle mass measures.

In summary, the concordance between BIA and CT was high. For BIA_{FFMI}, BIA_{ASMI} and MAMC, specificity was high, but sensitivity was low. CT remains the first choice in detecting low muscle mass in clinical practice. However, both BIA and MAMC could be used to detect low muscle mass in clinical practice. Since these tools are easy to perform by dieticians, they might be well suited for routine assessment of muscle mass in clinical practice.

Author Contributions: D.G.-v.D. was mainly responsible for the conception and design of the study, data analysis, and writing the manuscript. M.J.E.C.-K. and R.L. contributed to the conception and design of the study and interpretation of the data. G.D., J.-W.H., M.J.E.C.-K. and P.H.J.H. designed both original studies. L.B.M.W. developed protocols for the analyses of CT-scans. L.B.M.W. and M.M. contributed to the analysis of the CT-scans. All authors have read and agreed to the published version of the manuscript.

Funding: No funding was required for the conduction of this study. The original data from the SPOT study was funded by Baxter Grant no GHOL6687 and from the SMal-Hipec study by the BBraun Grant no HC-IO-H-1707. Additionally, the use of the equipment was sponsored by Fresenius Kabi and BBraun.

Institutional Review Board Statement: Both studies were conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of UMCG. The SMal-HIPEC study was approved (protocol code METc 2016/272; on 20 October 2016), and the SPOT ethical review and approval were waived (protocol code METc 2016/348).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets of the current study are not publicly available, but are available from the corresponding author on reasonable request.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Zhang, L.; Lu, Y.; Fang, Y. Nutritional status and related factors of patients with advanced gastrointestinal cancer. *Br. J. Nutr.* 2014, 111, 1239–1244. [CrossRef]
2. Prado, C.M.; Sawyer, M.B.; Ghosh, S.; Lieffers, J.R.; Esfandiari, N.; Antoun, S.; Baracos, V.E. Central tenet of cancer cachexia therapy: Do patients with advanced cancer have exploitable anabolic potential? *Am. J. Clin. Nutr.* 2013, 98, 1012–1019. [CrossRef]
3. Cederholm, T.; Bosaeus, I; Barazzoni, R.; Bauer, J.; Van Gossum, A.; Klek, S.; Muscaritoli, M.; Nyulasi, I; Ockenga, J.; Schneider, S.M.; et al. Diagnostic criteria for malnutrition—An ESPEN Consensus Statement. *Clin. Nutr.* 2015, 34, 335–340. [CrossRef]
4. Martin, L.; Birdsell, L.; Macdonald, N.; Reiman, T.; Clandinin, M.T.; McCargar, L.J.; Murphy, R.; Ghosh, S.; Sawyer, M.B.; Baracos, V.E. Cancer cachexia in the age of obesity: Skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. *J. Clin. Oncol.* 2013, 31, 1539–1547. [CrossRef]
5. Prado, C.M.; Baracos, V.E.; McCargar, L.J.; Reiman, T.; Mourtzakis, M.; Tonkin, K.; Mackey, J.R.; Koski, S.; Pituskin, E.; Sawyer, M.B. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. *Clin. Canc. Res.* 2009, 15, 2920–2926. [CrossRef]
6. Yip, C.; Goh, V.; Davies, A.; Gossage, J.; Mitchell-Hay, R.; Hynes, O.; Maisey, N.; Ross, P.; Gay, A.; Landau, D.B.; et al. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. *Eur. Radiol.* 2014, 24, 998–1005. [CrossRef] [PubMed]
7. Rutten, I.J.; van Dijk, D.P.; Kruitwagen, R.F.; Beets-Tan, R.G.; Olde Damink, S.W.; van Gorp, T. Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. *J. Cachexia Sarcopenia Muscle* 2016, 7, 458–466. [CrossRef] [PubMed]
8. Pichard, C.; Kyle, U.G.; Morabia, A.; Perrier, A.; Vermeulen, B.; Unger, P. Nutritional assessment: Lean body mass depletion at hospital admission is associated with an increased length of stay. Am. J. Clin. Nutr. 2004, 79, 613–618. [CrossRef] [PubMed]
9. Miyamoto, Y.; Baba, Y.; Sakamoto, Y.; Ohuchi, M.; Tokunaga, R.; Kurashige, J.; Hiyoshi, Y.; Iwagami, S.; Yoshida, N.; Watanabe, M.; et al. Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer. PLoS ONE 2015, 10, e0129742. [CrossRef] [PubMed]
10. Caro, M.M.; Laviano, A.; Pichard, C.; Candela, C.G. Relationship between nutritional intervention and quality of life in cancer patients. Nutr. Hosp. 2007, 22, 337–350.
11. Arends, J.; Bachmann, P.; Baracos, V.; Barthelemy, N.; Bertz, H.; Bozzetti, F.; Fearon, K.; Hutterer, E.; Isenring, E.; Kaasa, S.; et al. ESPEN guidelines on nutrition in cancer patients. Clin. Nutr. 2017, 36, 11–48. [CrossRef]
12. Isenring, E.; Zabel, R.; Bannister, M.; Brown, T.; Findlay, M.; Kiss, N.; Loeliger, J.; Stonehouse, W.; et al. Updated evidence-based practice guidelines for the nutritional management of patients receiving radiation therapy and/or chemotherapy. J. Nutr. Diet. 2013, 70, 312–324. [CrossRef]
13. Ravasco, P.; Monteiro-Grillo, I.; Camila, M. Individualized nutrition intervention is of major benefit to colorectal cancer patients: Long-term follow-up of a randomized controlled trial of nutritional therapy. Am. J. Clin. Nutr. 2012, 96, 1346–1353. [CrossRef] [PubMed]
14. Khan, M.; Hui, K.; McCauley, S.M. What Is a Registered Dietitian Nutritionist’s Role in Addressing Malnutrition? J. Acad. Nutr. Diet. 2018, 118, 1804. [CrossRef]
15. Fleurke, M.; Voskuil, D.W.; Kolmer, D.M.B. G. The role of the dietitian in the management of malnutrition in the elderly: A systematic review of current practices. Nutr. Diet. 2020, 77, 60–75. [CrossRef] [PubMed]
16. Luther, A.; Gabriel, J.; Watson, R.P.; Francis, N.K. The Impact of Total Body Prehabilitation on Post-Operative Outcomes After Major Abdominal Surgery: A Systematic Review. World J. Surg. 2018, 42, 2781–2791. [CrossRef] [PubMed]
17. Brown, J.C.; Caan, B.J.; Meyerhardt, J.A.; Weltzien, E.; Xiao, J.; Feliciano, E.M.C.; Kroenke, C.H.; Castillo, A.; Kwan, M.L.; Prado, C.M. The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I-III colorectal cancer: A population-based cohort study (C-SCANS). J. Cachexia Sarcopenia Muscle 2018, 9, 664–672. [CrossRef]
18. Prado, C.M.; Siervo, M.; Mire, E.; Heymsfield, S.B.; Stephan, B.C.; Broyles, S.; Smith, S.R.; Wells, J.C.; Katzmarzyk, P.T.; Baracos, V. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Nutr. Diet. 2020, 77, 1369–1377. [CrossRef] [PubMed]
19. Rier, H.N.; Jager, A.; Sleijfer, S.; Maier, A.B.; Levin, M.D. The Prevalence and Prognostic Value of Low Muscle Mass in Cancer Patients: A Review of the Literature. Oncol. 2016, 21, 1396–1409. [CrossRef] [PubMed]
20. Prado, C.M.; Liefers, J.R.; McCargar, L.J.; Reiman, T.; Sawyer, M.B.; Martin, L.; Baracos, V.E. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol. 2008, 9, 629–635. [CrossRef]
21. Bauer, J.; Capra, S.; Ferguson, M. Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. Eur. J. Clin. Nutr. 2002, 56, 779–785. [CrossRef]
22. Ottery, F.D. Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition 1996, 12 (Suppl. 1), S15–S19. [CrossRef]
23. Detsky, A.S.; McLaughlin, J.R.; Baker, J.P.; Johnston, N.; Whittaker, S.; Mendelson, R.A.; Jeejeebhoy, K.N. What is subjective global assessment of nutritional status? J. Parenter Enteral Nutr. 1987, 11, 8–13. [CrossRef]
24. Wiepert, E.V.M.; Padilha, P.C.; Peres, W.A.F. Performance of Patient-Generated Subjective Global Assessment (PG-SGA) in Patients With Advanced Cancer in Palliative Care. Nutr. Clin. Pract. 2017, 32, 675–681. [CrossRef] [PubMed]
25. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39, 412–423. [CrossRef] [PubMed]
26. Teigen, L.M.; Kuchnia, A.J.; Mauritzen, M.; Earthman, C.P. The Use of Technology for Estimating Body Composition: Strengths and Weaknesses of Common Modalities in a Clinical Setting [Formula: See text]. Nutr. Clin. Pract. 2017, 32, 20–29. [CrossRef] [PubMed]
27. Isenring, E.; Zabel, R.; Bannister, M.; Brown, T.; Findlay, M.; Kiss, N.; Loeliger, J.; Stonehouse, W.; et al. Updated evidence-based practice guidelines for the nutritional management of patients receiving radiation therapy and/or chemotherapy. J. Nutr. Diet. 2013, 70, 312–324. [CrossRef]
28. Teigen, L.M.; Kuchnia, A.J.; Mauritzen, M.; Earthman, C.P. The Use of Technology for Estimating Body Composition: Strengths and Weaknesses of Common Modalities in a Clinical Setting [Formula: See text]. Nutr. Clin. Pract. 2017, 32, 20–29. [CrossRef] [PubMed]
29. Raeder, H.; Kvaerner, A.S.; Henriksen, C.; Florholmen, G.; Henriksen, H.B.; Bohn, S.K.; Paur, I.; Smeland, S.; Blomhoff, R. Validity of bioelectrical impedance analysis in estimation of fat-free mass in colorectal cancer patients. Clin. Nutr. 2017, 37, 292–300. [CrossRef]
32. Wijnhoven, H.A.; van Bokhorst-de van der Schueren, M.A.; Heymans, M.W.; de Vet, H.C.; Kruizenga, H.M.; Twisk, J.W.; Visser, M. Low mid-upper arm circumference, calf circumference, and body mass index and mortality in older persons. J. Gerontol. 2010, 65, 1107–1114. [CrossRef] [PubMed]

33. Janssens, I.; Heymsfield, S.B.; Baumgartner, R.N.; Ross, R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J. Appl. Physiol. 2000, 89, 465–471. [CrossRef] [PubMed]

34. Jensen, G.L.; Cederholm, T.; Correia, M.; Gonzalez, M.C.; Fukushima, R.; Higashiguchi, T.; de Baptista, G.A.; Barazzoni, R.; Blaauw, R.; Coats, A.J.S.; et al. GLM Criteria for the Diagnosis of Malnutrition: A Consensus Report From the Global Clinical Nutrition Community. J. Parenter Enteral Nutr. 2019, 43, 32–40. [CrossRef] [PubMed]

35. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013, 310, 2191–2194. [CrossRef] [PubMed]

36. Ozawa, Y.; Nakano, T.; Taniyama, Y.; Sakurai, T.; Onodera, Y.; Kamiya, K.; Hikage, M.; Sato, C.; Takaya, K.; Konno, T.; et al. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy. Esophagus 2019, 16, 345–351. [CrossRef]

37. Seca. Available online: https://www.seca.com/nl_nl/producenten/alle-producenten/produkt-details/seca525.html (accessed on 8 April 2021).

38. Schutz, Y.; Kyle, U.U.; Pichard, C. Fat-free mass index and fat mass index percentiles in Caucasians aged 18–98 y. Int. J. Obes. Relat. Metab. Disord. 2002, 26, 953–960. [CrossRef]

39. Sergi, G.; De Rui, M.; Veronese, N.; Bolzetta, F.; Berton, L.; Carraro, S.; Bano, G.; Coin, A.; Manzato, E.; Perissinotto, E. Assessing appendicular skeletal muscle mass with bioelectrical impedance analysis in free-living Caucasian older adults. Clin. Nutr. 2015, 34, 667–673. [CrossRef]

40. Gould, H.; Brennan, S.L.; Kotowicz, M.A.; Nicholson, G.C.; Pasco, J.A. Total and appendicular lean mass reference ranges for Australian men and women: The Geelong osteoporosis study. Calcif. Tissue Int. 2014, 94, 363–372. [CrossRef]

41. Frisancho, A.R. New standards of weight and body composition by frame size and height for assessment of nutritional status of adults and the elderly. Am. J. Clin. Nutr. 1984, 40, 808–819. [CrossRef]

42. Sealy, M.J.; Hass, U.; Ottery, F.D.; van der Schans, C.P.; Roodenburg, J.L.N.; Jager-Wittenaar, H. Translation and Cultural Adapta-

43. Ozawa, Y.; Nakano, T.; Taniyama, Y.; Sakurai, T.; Onodera, Y.; Kamiya, K.; Hikage, M.; Sato, C.; Takaya, K.; Konno, T.; et al. Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy. Esophagus 2019, 16, 345–351. [CrossRef]

37. Seca. Available online: https://www.seca.com/nl_nl/producenten/alle-producenten/produkt-details/seca525.html (accessed on 8 April 2021).

44. Vigano, A.; Del Fabbro, E.; Bruera, E.; Borod, M. The cachexia clinic: From staging to managing nutritional and functional

45. Vit-Global. Available online: https://pt-global.org/ (accessed on 8 April 2021).

46. Cicchetti, D.V. Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in

47. Glas, A.S.; Lijmer, J.G.; Prins, M.H.; Bonsel, G.J.; Bossuyt, P.M. The diagnostic odds ratio: A single indicator of test performance. Nutr. Cancer 2013, 65, 234–239. [CrossRef] [PubMed]

48. Looijaard, W.; Stapel, S.N.; Dekker, I.M.; Rusticus, H.; Remmelzwaal, S.; Girbes, A.R.J.; Weijs, P.J.M.; Oudemans-van Straaten, H.M. Identifying critically ill patients with low muscle mass: Agreement between bioelectrical impedance analysis and computed tomography. Clin. Nutr. 2019, 38, 41, 450–462. [CrossRef]

49. Giusto, M.; Lattanzi, B.; Albanese, C.; Galtieri, A.; Farcomeni, A.; Giannelli, V.; Lucidi, C.; Di Martino, M.; Catalano, C.; Merli, M. Sarcopenia in liver cirrhosis: The role of computed tomography scan for the assessment of muscle mass compared with digital photography. Nutr. Int. J. Obes. 2019, 35, 345–351. [CrossRef] [PubMed]

50. Garth, A.K.; Newsome, C.M.; Simmance, N.; Crowe, T.C. Nutritional status, nutrition practices and post-operative complications in patients with gastrointestinal cancer. J. Hum. Nutr. Diet. 2010, 23, 393–401. [CrossRef]

51. Weerink, L.B.M.; van der Hoorn, A.; van Leeuwen, B.L.; de Bock, G.H. Low skeletal muscle mass and postoperative morbidity in surgical oncology: A systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle 2014, 9, 636–649. [CrossRef]

52. Hopkins, J.J.; Skubleny, D.; Bigam, D.L.; Baracos, V.E.; Eurich, D.T.; Sawyer, M.B. Barriers to the Interpretation of Body

53. Kyle, U.G.; Bosaeus, I.; De Lorenzo, A.D.; Deurenberg, P.; Elia, M.; Manuel, G.J.; Lilienthal, H.B.; Kent-Smith, L.; Melchior, J.C.; Pirlich, M.; et al. Bioelectrical impedance analysis-part II: Utilization in clinical practice. Clin. Nutr. 2004, 23, 1430–1453. [CrossRef]
56. Landi, F.; Camprubi-Robles, M.; Bear, D.E.; Cederholm, T.; Malafarina, V.; Welch, A.A.; Cruz-Jentoft, A.J. Muscle loss: The new malnutrition challenge in clinical practice. *Clin. Nutr.* 2019, 38, 2113–2120. [CrossRef] [PubMed]

57. Deutz, N.E.P.; Ashurst, I.; Ballesteros, M.D.; Bear, D.E.; Cruz-Jentoft, A.J.; Genton, L.; Landi, F.; Laviano, A.; Norman, K.; Prado, C.M. The Underappreciated Role of Low Muscle Mass in the Management of Malnutrition. *J. Am. Med. Dir. Assoc.* 2019, 20, 22–27. [CrossRef]

58. Klassen, P.; Baracos, V.; Gramlich, L.; Nelson, G.; Mazurak, V.; Martin, L. Computed-Tomography Body Composition Analysis Complements Pre-Operative Nutrition Screening in Colorectal Cancer Patients on an Enhanced Recovery after Surgery Pathway. *Nutrients* 2020, 12, 3745. [CrossRef] [PubMed]

59. Mulasi, U.; Kuchnia, A.J.; Cole, A.J.; Earthman, C.P. Bioimpedance at the bedside: Current applications, limitations, and opportunities. *Nutr. Clin. Pract.* 2015, 30, 180–193. [CrossRef]